Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%

Stock buyback support
Stock Buyback 3Y Total is 1.2 Bil

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -59%, 3Y Excs Rtn is -116%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 19x, P/EPrice/Earnings or Price/(Net Income) is 31x

Key risks
ALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
1 Stock buyback support
Stock Buyback 3Y Total is 1.2 Bil
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Remote Patient Monitoring, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -59%, 3Y Excs Rtn is -116%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 19x, P/EPrice/Earnings or Price/(Net Income) is 31x
5 Key risks
ALGN key risks include [1] intensified competition and pricing pressure following the expiration of its key patents and [2] costly intellectual property litigation and regulatory scrutiny.

ALGN in ETFs

Weight = ALGN's share of each fund

SPY0.02%
VOO0.02%
IVV0.02%
VTI0.02%
ITOT0.02%
IWB0.02%
RSP0.21%
VB0.15%
+24 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 7/1/2026

Align Technology (ALGN) stock has gained about 10% since 3/31/2026 because of the following key factors:

1. Align Technology exceeded fiscal Q1 2026 earnings expectations with a non-GAAP diluted EPS of $2.58, significantly beating the consensus analyst estimate of $2.18 by 18.35%. This strong financial performance for the quarter ending March 31, 2026, also included revenues of $1.0401 billion, a 6.2% year-over-year increase, surpassing the $1.02 billion forecast.

2. The company achieved record Clear Aligner shipments in fiscal Q1 2026, reaching 685.7 thousand cases, which marked a 6.7% increase year-over-year. This growth was primarily fueled by robust double-digit expansion in international markets, including Europe, the Middle East and Africa (EMEA), Asia Pacific (APAC), and Latin America (LATAM), while the North American market remained stable.

Show more
Updated on 7/1/2026

Align Technology (ALGN) stock has gained about 10% since 3/31/2026 because of the following key factors:

1. Align Technology exceeded fiscal Q1 2026 earnings expectations with a non-GAAP diluted EPS of $2.58, significantly beating the consensus analyst estimate of $2.18 by 18.35%. This strong financial performance for the quarter ending March 31, 2026, also included revenues of $1.0401 billion, a 6.2% year-over-year increase, surpassing the $1.02 billion forecast.

2. The company achieved record Clear Aligner shipments in fiscal Q1 2026, reaching 685.7 thousand cases, which marked a 6.7% increase year-over-year. This growth was primarily fueled by robust double-digit expansion in international markets, including Europe, the Middle East and Africa (EMEA), Asia Pacific (APAC), and Latin America (LATAM), while the North American market remained stable.

3. Align Technology announced a new $200 million stock repurchase program, reaffirming its commitment to shareholder value. This program, part of a larger $1.0 billion authorization, commenced around May 1, 2026, and is expected to be completed over six months.

4. Analyst sentiment remained largely positive throughout fiscal Q2 2026, with a consensus "Moderate Buy" rating and an average price target of approximately $208.00 to $209.07. This indicated a potential upside of 14.61% to 17.17% from the prevailing stock price, contributing to investor confidence following the strong Q1 2026 results.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 8.0% change in ALGN stock from 3/31/2026 to 7/7/2026 was primarily driven by a 3.2% change in the company's Net Income Margin (%).
(LTM values as of)33120267072026Change
Stock Price ($)171.43185.228.0%
Change Contribution By: 
Total Revenues ($ Mil)4,0354,0961.5%
Net Income Margin (%)10.2%10.5%3.2%
P/E Multiple29.930.82.8%
Shares Outstanding (Mil)72710.4%
Cumulative Contribution8.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2026 to 7/7/2026
ReturnCorrelation
ALGN8.0% 
Market (SPY)15.0%42.8%
Sector (XLV)12.2%30.5%

Fundamental Drivers

The 18.6% change in ALGN stock from 12/31/2025 to 7/7/2026 was primarily driven by a 10.5% change in the company's Net Income Margin (%).
(LTM values as of)123120257072026Change
Stock Price ($)156.15185.2218.6%
Change Contribution By: 
Total Revenues ($ Mil)3,9834,0962.8%
Net Income Margin (%)9.5%10.5%10.5%
P/E Multiple29.930.83.0%
Shares Outstanding (Mil)72711.3%
Cumulative Contribution18.6%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 7/7/2026
ReturnCorrelation
ALGN18.6% 
Market (SPY)9.9%50.7%
Sector (XLV)6.7%34.1%

Fundamental Drivers

The -2.2% change in ALGN stock from 6/30/2025 to 7/7/2026 was primarily driven by a -9.5% change in the company's P/E Multiple.
(LTM values as of)63020257072026Change
Stock Price ($)189.33185.22-2.2%
Change Contribution By: 
Total Revenues ($ Mil)3,9814,0962.9%
Net Income Margin (%)10.3%10.5%2.0%
P/E Multiple34.030.8-9.5%
Shares Outstanding (Mil)74713.0%
Cumulative Contribution-2.2%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2025 to 7/7/2026
ReturnCorrelation
ALGN-2.2% 
Market (SPY)22.0%36.2%
Sector (XLV)23.6%41.1%

Fundamental Drivers

The -47.6% change in ALGN stock from 6/30/2023 to 7/7/2026 was primarily driven by a -64.4% change in the company's P/E Multiple.
(LTM values as of)63020237072026Change
Stock Price ($)353.64185.22-47.6%
Change Contribution By: 
Total Revenues ($ Mil)3,7054,09610.6%
Net Income Margin (%)8.5%10.5%23.4%
P/E Multiple86.330.8-64.4%
Shares Outstanding (Mil)77717.7%
Cumulative Contribution-47.6%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2023 to 7/7/2026
ReturnCorrelation
ALGN-47.6% 
Market (SPY)74.6%45.6%
Sector (XLV)29.7%35.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ALGN Return23%-68%30%-24%-25%21%-65%
Peers Return41%-33%-9%-31%-15%27%-35%
S&P 500 Return27%-19%24%23%16%10%101%

Monthly Win Rates [3]
ALGN Win Rate50%33%58%42%67%57% 
Peers Win Rate50%40%48%42%42%64% 
S&P 500 Win Rate75%42%67%75%67%57% 

Max Drawdowns [4]
ALGN Max Drawdown-20%-73%-52%-38%-47%-21% 
Peers Max Drawdown-33%-47%-47%-46%-45%-28% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: NVST, XRAY, HSIC, DDD. See ALGN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/7/2026 (YTD)

How Low Can It Go

EventALGNS&P 500
2025 US Tariff Shock
  % Loss-28.5%-18.8%
  % Gain to Breakeven39.8%23.1%
  Time to Breakeven93 days79 days
2024 Yen Carry Trade Unwind
  % Loss-18.1%-7.8%
  % Gain to Breakeven22.1%8.5%
  Time to Breakeven40 days18 days
2023 SVB Regional Banking Crisis
  % Loss-13.9%-6.7%
  % Gain to Breakeven16.1%7.1%
  Time to Breakeven21 days31 days
2020 COVID-19 Crash
  % Loss-50.3%-33.7%
  % Gain to Breakeven101.2%50.9%
  Time to Breakeven74 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-50.8%-19.2%
  % Gain to Breakeven103.1%23.8%
  Time to Breakeven658 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-11.1%-3.7%
  % Gain to Breakeven12.4%3.9%
  Time to Breakeven21 days6 days

Compare to NVST, XRAY, HSIC, DDD

In The Past

Align Technology's stock fell -28.5% during the 2025 US Tariff Shock. Such a loss loss requires a 39.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventALGNS&P 500
2025 US Tariff Shock
  % Loss-28.5%-18.8%
  % Gain to Breakeven39.8%23.1%
  Time to Breakeven93 days79 days
2020 COVID-19 Crash
  % Loss-50.3%-33.7%
  % Gain to Breakeven101.2%50.9%
  Time to Breakeven74 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-50.8%-19.2%
  % Gain to Breakeven103.1%23.8%
  Time to Breakeven658 days105 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-40.6%-17.9%
  % Gain to Breakeven68.4%21.8%
  Time to Breakeven58 days123 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-22.6%-15.4%
  % Gain to Breakeven29.2%18.2%
  Time to Breakeven47 days125 days
2008-2009 Global Financial Crisis
  % Loss-72.5%-53.4%
  % Gain to Breakeven263.0%114.4%
  Time to Breakeven438 days1085 days

Compare to NVST, XRAY, HSIC, DDD

In The Past

Align Technology's stock fell -28.5% during the 2025 US Tariff Shock. Such a loss loss requires a 39.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Align Technology (ALGN)

Align Technology, Inc. (ALGN) is a global medical device company that innovates in digital dentistry, primarily known for its clear aligner solutions and advanced intraoral scanning technology. The company designs, manufactures, and markets products that transform orthodontic and restorative dental treatments.

Its core offering is the Invisalign system, a comprehensive suite of custom-made clear aligners that serve as an aesthetic and often more comfortable alternative to traditional metal braces. Invisalign treatments cater to a wide range of patients, from young children needing early intervention to teenagers and adults requiring full orthodontic correction. Complementing the aligners, Align Technology also provides retention products, professional training, and various ancillary treatment tools.

The company's other significant segment includes its iTero intraoral scanners and associated services. These high-precision scanners create digital 3D images of teeth, eliminating the need for traditional dental impressions. The iTero platform is supported by sophisticated software for orthodontic diagnosis, treatment planning, and restorative procedures, including tools for outcome simulation and progress assessment. Align Technology primarily serves orthodontists, general practitioner dentists, and other dental specialists globally, empowering them to deliver modern digital dental care.

AI Analysis | Feedback

1. Tesla for teeth straightening

2. Apple for orthodontics

AI Analysis | Feedback

  • Invisalign Clear Aligners: A comprehensive line of transparent, removable aligners designed for orthodontic treatment across various age groups and complexities.
  • iTero Intraoral Scanners: Advanced digital scanning hardware platforms that capture 3D images of teeth and gums for use in restorative and orthodontic procedures.
  • iTero Software Solutions: Specialized software applications for iTero scanners, providing functionalities for restorative dentistry, orthodontic diagnosis, digital record storage, and model/retainer fabrication.
  • Dental CAD/CAM Services: Computer-aided design and manufacturing services supporting the fabrication of various dental appliances and models.
  • Invisalign Ancillary Products & Training: Includes retention products, cleaning materials, adjusting tools, and professional training fees for dental practitioners utilizing the Invisalign system.
  • iTero Ancillary Products & Digital Tools: Consists of disposable scanner sleeves, models and dies, and digital applications such as the Invisalign Outcome Simulator, Progress Assessment tool, and TimeLapse technology.

AI Analysis | Feedback

Align Technology (ALGN) primarily sells its products and services to other businesses, specifically dental professionals and their practices, rather than directly to individual consumers. The company's major customers are not large, publicly traded companies that can be listed by name and symbol. Instead, Align Technology serves a broad base of dental professionals who operate their own clinics and practices.

The categories of dental professionals that Align Technology serves are:

  1. Orthodontists: Specialists who diagnose, prevent, and treat dental and facial irregularities. They are key users of Invisalign clear aligners and iTero intraoral scanners for orthodontic procedures and digital records.
  2. General Practitioner Dentists (GPs): Dentists who provide primary dental care, including restorative and aesthetic dentistry. They utilize Invisalign for moderate, lite, and express treatments, as well as iTero scanners for restorative procedures.
  3. Other Dental Specialists: This category includes professionals such as prosthodontists (specializing in dental prosthetics), periodontists (specializing in gum health), and oral surgeons, who use iTero intraoral scanners and associated software for restorative procedures, digital records, and treatment planning.

AI Analysis | Feedback

null

AI Analysis | Feedback

Joseph M. Hogan, President and Chief Executive Officer

Joseph M. Hogan joined Align Technology in June 2015 as President, Chief Executive Officer (CEO), and a Director. Mr. Hogan is an accomplished executive with extensive experience across multiple industries, including healthcare, technology, and industrial automation. Before joining Align, he served as CEO of ABB, a global power and automation technologies company, where he oversaw a 25% increase in revenues during his five-year tenure. Prior to ABB, Mr. Hogan spent 25 years at General Electric (GE) in various executive and management roles, including eight years as CEO of GE Healthcare. At GE Healthcare, he significantly expanded geographic and market portfolios, more than doubling revenues from $7 billion to $16 billion. He earned an M.B.A. from Robert Morris University and a B.S. degree in Business and Economics from Geneva College.

John F. Morici, Chief Financial Officer and Executive Vice President, Global Finance

John F. Morici joined Align Technology in November 2016 as Chief Financial Officer (CFO) and Executive Vice President of Global Finance. He is responsible for managing the company's global finance and financial strategy. With over two decades of experience, Mr. Morici has held senior leadership positions in finance, operations, and strategic planning within healthcare, medical technology, and consumer/entertainment sectors. Before Align, he spent nine years at NBC Universal, where he held several senior management positions in its Universal Pictures Home Entertainment U.S. and Canadian businesses, including CFO, COO, and Executive Vice President and Managing Director. In his role as Executive Vice President and Managing Director at NBC Universal, he led all finance, sales, marketing, operations, and customer service organizations, and was responsible for overall strategy and planning. Prior to NBC Universal, Mr. Morici spent eight years in senior financial management positions at GE Healthcare, serving as CFO for its Diagnostic Imaging and Global Products units. He also held financial management roles at Case New Holland and Abbott Laboratories. Mr. Morici holds an M.B.A. in Finance and a B.S. in Molecular Biology, both from the University of Wisconsin.

Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer

Julie Coletti is the Executive Vice President, Chief Legal and Regulatory Officer of Align Technology, leading the company's global legal, regulatory, and quality teams. She also serves as corporate secretary to Align Technology Inc.'s Board of Directors. Ms. Coletti joined Align in May 2018 as Vice President, Associate General Counsel, Strategic Commercial Affairs, and was promoted to her current position in May 2019. She is an experienced life sciences and technology executive, general counsel, and chief compliance officer. Before Align, she served as Vice President and Global General Counsel of Danaher Corporation's $3 billion dental medical device platform. Prior to Danaher, she was Vice President, Chief Legal Officer, and Corporate Secretary at Bayer HealthCare's MEDRAD/Radiology and Interventional Division. Ms. Coletti began her career in litigation at LeBoeuf, Lamb, Greene & MacRae LLP. She received her J.D. from the University of Pittsburgh and her B.A. from Rutgers University. She also serves as a director for Fortis Life Sciences.

Raj Pudipeddi, Executive Vice President, Chief Product & Marketing Officer and Managing Director, Asia Pacific

Raj Pudipeddi joined Align Technology in 2019 as Senior Vice President and Chief Marketing Officer. In his current dual roles, he has global responsibility for product, marketing, innovation, business development, and clinical teams, as well as for the market development and commercial execution of all Align Technology products and services in the Asia Pacific region. Mr. Pudipeddi possesses 26 years of business leadership and brand-building experience across consumer goods and telecom. He began his career at Procter & Gamble, where he spent nearly 22 years in various leadership roles across businesses in North America, Asia, and Latin America. Most recently, before joining Align, he served as Chief Marketing Officer and Director, Consumer Business at Bharti Airtel, an Indian telecom leader. Mr. Pudipeddi earned an M.B.A. degree from the Indian Institute of Management, Lucknow, and a Bachelor of Engineering degree from the Gandhi Institute of Technology. He is also an Independent Director at Sonendo, Inc. and a Board Advisor at Spark Venture Capital LLC.

Stuart Hockridge, Executive Vice President, Global Human Resources

Stuart Hockridge serves as the Executive Vice President, Global Human Resources at Align Technology. He started at Align Technology in May 2016. Prior to Align, Mr. Hockridge held senior leadership roles in human resources for global companies.

AI Analysis | Feedback

The key risks to Align Technology's business include intense competition and pricing pressure, macroeconomic sensitivity affecting demand, and ongoing intellectual property and litigation challenges.

The orthodontic industry is characterized by **intense competition and pricing pressure**. Align Technology faces significant competition from established dental companies like 3M Company, Dentsply Sirona Inc., and Danaher Corporation, which offer traditional orthodontic products and alternative clear aligner systems such as Clarity Aligners and SureSmile aligners. New entrants, including direct-to-consumer companies and those offering 3D printing alternatives, also contribute to a highly competitive landscape. This competitive environment has led to pricing pressure, resulting in a decline in the Average Selling Price (ASP) for Align's clear aligner products and impacting its overall profitability. The company has responded by shifting towards lower-priced, non-comprehensive aligner options, which further compresses margins.

Align Technology is highly susceptible to **macroeconomic sensitivity and fluctuating demand**. Orthodontic procedures, particularly for adults, are often considered discretionary healthcare spending, making them vulnerable to global economic uncertainties, recessions, and downturns. Fluctuations in foreign currency exchange rates also pose a significant headwind, as a substantial portion of Align's revenues are generated internationally. Economic issues, including inflation, geopolitical complications, and rising interest rates, have led to a "substantial slowdown in new orthodontic appointments and adult case starts in North America," directly impacting the company's revenue and necessitating restructuring efforts.

The company also faces **intellectual property and litigation risks**. While Align Technology possesses a robust portfolio of patents and actively defends its innovations, the expiration of some core Invisalign patents in 2017 increased competitive threats. Align is currently engaged in significant patent infringement lawsuits against competitors, such as Angelalign Technology, across multiple international jurisdictions including the United States, Europe, and China, to protect its patented technologies and substantial research and development investments. Additionally, the company has faced antitrust class action lawsuits, although it has received favorable rulings in some cases.

AI Analysis | Feedback

The emerging threat to Align Technology is the increasing capability and adoption by dental professionals of in-house 3D printing for the direct fabrication of clear aligners. As 3D printing technology becomes more accessible, affordable, and accurate, and alongside the development of user-friendly third-party design software, orthodontists and general practitioner dentists may choose to produce custom clear aligners for their patients directly within their own practices or through smaller, local labs. This trend could bypass Align Technology's traditional manufacturing and sales model for its Invisalign clear aligner products, thereby cutting into its primary revenue stream from the Clear Aligner segment by disintermediating Align as the central aligner manufacturer.

AI Analysis | Feedback

Align Technology's main products, Invisalign clear aligners and iTero intraoral scanners, operate within significant and growing addressable markets.

Clear Aligners Market

The global clear aligners market was estimated to be between USD 8.29 billion and USD 8.51 billion in 2025. Projections indicate substantial growth, with the market expected to reach approximately USD 56.81 billion by 2033 or USD 113.64 billion by 2035. North America consistently holds the largest share of this market, accounting for approximately 54.57% in 2025. The U.S. clear aligners market alone was valued at USD 2.17 billion in 2023 and is projected to reach USD 14.83 billion by 2033.

Intraoral Scanners Market

The global intraoral scanners market was valued between USD 770.4 million and USD 824.70 million in 2025. This market is forecasted to grow to approximately USD 1.68 billion by 2035 or USD 1.6 billion by 2035. North America dominated the intraoral scanners market in 2025. Specifically, the North American dental intraoral scanners market was valued at USD 277.37 million in 2024 and is anticipated to reach USD 814.96 million by 2033.

AI Analysis | Feedback

Align Technology (ALGN) is expected to drive future revenue growth over the next two to three years through several key strategies:

  1. Global Expansion and Increased Adoption of Clear Aligners Across Patient Segments: Align Technology anticipates continued growth by expanding the adoption of its Invisalign clear aligners across different patient demographics, including teenagers, younger patients (Invisalign First), and adults. This expansion is observed globally, particularly in under-penetrated international markets such as the Asia Pacific (APAC) and EMEA regions, with China identified as a significant opportunity. The company also expects higher utilization of Invisalign among orthodontists transitioning from traditional methods. Additionally, the expansion of the Invisalign Doctor Subscription Program (DSP) for touch-up cases is contributing to this growth.
  2. Innovation and Market Penetration of Imaging Systems and CAD/CAM Services: The launch and ramp-up of new technologies, such as the iTero Lumina intraoral scanner, are crucial drivers. Align Technology is also focusing on expanding restorative workflows for its iTero Lumina scanners and introducing new products like the Invisalign Palatal Expander System, which has broad patient applicability. Strategic investments in areas like AI-driven treatment planning and direct 3D printing, through acquisitions like Cubicure GmbH, are expected to further enhance their digital dentistry offerings and drive revenue in the Scanners and Services segment.
  3. Strengthening Partnerships and Engagement with Dental Service Organizations (DSOs): Align Technology is strategically focusing on Dental Service Organizations (DSOs) as a significant channel for growth. The company has observed double-digit growth from DSOs across North America, Latin America, APAC, and Europe. By strengthening ties and standardizing workflows with DSOs, Align aims to broaden its reach within the dental community and increase the adoption and utilization of its products and services.

AI Analysis | Feedback

Share Repurchases

  • Align Technology authorized a new $1.0 billion stock repurchase program in May 2025, which is expected to be executed over the next three years.
  • The company completed a previous $1.0 billion stock repurchase program, authorized in January 2023, by May 1, 2025.
  • Actual share repurchases amounted to $600 million in 2023, $353 million in 2024, and $465.9 million in 2025.

Share Issuance

  • Align Technology's executives and employees, including the EVP Global HR and the President and CEO, received and vested equity awards, leading to the acquisition of shares through derivative exercises or conversions between 2022 and 2025.
  • A shareholder filed a notice in February 2026 for the proposed sale of 7,969 common shares, which were acquired through performance stock unit vests in 2022, 2023, and 2024.

Inbound Investments

  • As of December 31, 2025, Capital International Investors held a 6.8% passive ownership stake in Align Technology, beneficially owning 4,881,512 shares.

Outbound Investments

  • In the first quarter of 2024, Align Technology completed the acquisition of Cubicure GmbH, a company specializing in direct 3D printing solutions, to support its next-generation aligner manufacturing.

Capital Expenditures

  • Capital expenditures were $401.1 million in 2021, $291.9 million in 2022, $177.7 million in 2023, and $115.6 million in 2024.
  • For fiscal year 2025, capital expenditures are estimated to be between $100 million and $125 million, primarily allocated to technology upgrades and maintenance. Forecasted capital expenditures for fiscal 2026 are expected to be between $125 million and $150 million, focusing on technology upgrades, additional manufacturing capacity, and maintenance.
  • In the second half of 2025, the company planned to optimize its manufacturing footprint and dispose of certain capital assets as it transitions to next-generation manufacturing technologies and increases automation, expecting one-time charges of approximately $150 million to $170 million, with about $40 million in cash outlays.

Better Bets vs. Align Technology (ALGN)

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Mkt Price185.2227.1312.1986.842.8727.13
Mkt Cap13.24.42.410.00.44.4
Rev LTM4,0962,8083,68113,3843883,681
Op Inc LTM623263211752-66263
FCF LTM584220104391-70220
FCF 3Y Avg569250220457-80250
CFO LTM692272268578-61272
CFO 3Y Avg689294378645-64378

Growth & Margins

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Rev Chg LTM2.9%12.1%-1.0%5.6%-10.2%2.9%
Rev Chg 3Y Avg3.4%3.3%-2.1%2.3%-9.7%2.3%
Rev Chg Q6.2%14.4%0.1%6.3%1.1%6.2%
QoQ Delta Rev Chg LTM1.5%3.3%0.0%1.5%0.3%1.5%
Op Inc Chg LTM-4.6%92.7%-0.5%-2.5%49.2%-0.5%
Op Inc Chg 3Y Avg2.2%10.1%-12.5%-2.1%15.0%2.2%
Op Mgn LTM15.2%9.4%5.7%5.6%-17.0%5.7%
Op Mgn 3Y Avg16.3%8.8%6.2%5.6%-23.4%6.2%
QoQ Delta Op Mgn LTM0.7%0.4%-1.1%-0.1%7.8%0.4%
CFO/Rev LTM16.9%9.7%7.3%4.3%-15.8%7.3%
CFO/Rev 3Y Avg17.2%11.2%10.0%5.0%-14.9%10.0%
FCF/Rev LTM14.2%7.8%2.8%2.9%-18.2%2.9%
FCF/Rev 3Y Avg14.2%9.6%5.8%3.6%-18.5%5.8%

Valuation

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
Mkt Cap13.24.42.410.00.44.4
P/S3.21.60.70.71.11.1
P/Op Inc21.216.911.513.3-6.313.3
P/EBIT21.218.9-5.114.44.614.4
P/E30.865.7-3.925.36.625.3
P/CFO19.116.39.117.3-6.716.3
Total Yield3.2%1.5%-21.8%4.0%15.2%3.2%
Dividend Yield0.0%0.0%3.9%0.0%0.0%0.0%
FCF Yield 3Y Avg4.1%7.1%6.0%5.2%-22.6%5.2%
D/E0.00.41.00.40.40.4
Net D/E-0.10.10.90.40.10.1

Returns

ALGNNVSTXRAYHSICDDDMedian
NameAlign Te.Envista Dentsply.Henry Sc.3D Syste. 
1M Rtn10.4%17.4%21.9%12.1%-1.4%12.1%
3M Rtn11.0%7.3%5.8%17.6%57.7%11.0%
6M Rtn10.5%16.9%-1.5%10.6%29.3%10.6%
12M Rtn-4.4%37.9%-21.4%18.2%75.0%18.2%
3Y Rtn-43.8%-19.6%-65.9%10.4%-69.9%-43.8%
1M Excs Rtn11.1%19.7%24.4%14.9%-5.5%14.9%
3M Excs Rtn-5.7%-8.4%-8.8%2.5%40.8%-5.7%
6M Excs Rtn9.3%15.7%-1.2%3.6%45.7%9.3%
12M Excs Rtn-25.5%15.0%-44.3%-2.9%54.4%-2.9%
3Y Excs Rtn-116.5%-90.2%-137.2%-63.3%-142.2%-116.5%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Clear Aligner3,2453,2303,1993,0733,247
Systems and Services790769663662706
Total4,0353,9993,8623,7353,953


Operating Income by Segment
$ Mil20252024202320222021
Clear Aligner1,0351,1421,1821,1341,326
Systems and Services306269191180259
Unallocated corporate expenses-795-804-730-672-609
Total546608643643976


Assets by Segment
$ Mil2011
Clear Aligner469
Scanners and CAD/CAM Services180
Total649


Price Behavior

Price Behavior
Market Price$185.22 
Market Cap ($ Bil)13.2 
First Trading Date01/30/2001 
Distance from 52W High-10.6% 
   50 Days200 Days
DMA Price$171.81$162.65
DMA Trendupdown
Distance from DMA7.8%13.9%
 3M1YR
Volatility45.2%54.1%
Downside Capture128.29189.80
Upside Capture107.60141.21
Correlation (SPY)42.2%36.1%
ALGN Betas & Captures as of 6/30/2026

 1M2M3M6M1Y3Y
Beta0.981.251.411.621.561.41
Up Beta0.230.851.751.851.961.56
Down Beta1.181.011.051.671.061.08
Up Capture97%111%89%161%169%168%
Bmk +ve Days11244067140429
Stock +ve Days10193161125364
Down Capture121%170%176%143%152%111%
Bmk -ve Days10172358112321
Stock -ve Days11223264126386

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN-4.5%54.1%0.15-
Sector ETF (XLV)23.0%15.7%1.1341.1%
Equity (SPY)20.7%12.5%1.2236.1%
Gold (GLD)23.0%27.8%0.7310.9%
Commodities (DBC)22.9%18.6%0.97-11.8%
Real Estate (VNQ)13.6%13.8%0.6835.3%
Bitcoin (BTCUSD)-41.8%42.8%-1.1417.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN-21.3%49.8%-0.29-
Sector ETF (XLV)7.1%14.9%0.2939.6%
Equity (SPY)13.3%17.1%0.6053.1%
Gold (GLD)17.8%18.3%0.797.3%
Commodities (DBC)7.6%19.5%0.296.6%
Real Estate (VNQ)3.1%18.9%0.0642.7%
Bitcoin (BTCUSD)13.2%53.5%0.4325.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ALGN
ALGN9.1%49.2%0.37-
Sector ETF (XLV)10.9%16.6%0.5447.4%
Equity (SPY)15.7%17.9%0.7555.8%
Gold (GLD)11.6%16.1%0.596.2%
Commodities (DBC)6.2%18.0%0.2715.1%
Real Estate (VNQ)5.6%20.7%0.2343.8%
Bitcoin (BTCUSD)57.9%66.2%0.9814.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date6152026
Short Interest: Shares Quantity4.7 Mil
Short Interest: % Change Since 53120261.8%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest5.1 days
Basic Shares Quantity71.4 Mil
Short % of Basic Shares6.6%

Earnings Returns History

Updated 6/2/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
4/29/2026-1.3%-2.5%-1.9%
2/4/20268.9%22.4%7.9%
10/29/20254.9%4.0%11.2%
7/30/2025-36.6%-32.8%-30.7%
4/30/20252.0%-0.6%4.4%
2/5/20250.9%-5.1%-19.7%
10/23/20244.2%1.5%9.9%
7/24/2024-7.7%-5.3%-6.6%
...
SUMMARY STATS   
# Positive131211
# Negative111213
Median Positive7.5%9.9%9.9%
Median Negative-7.7%-8.3%-12.2%
Max Positive35.0%30.9%31.4%
Max Negative-36.6%-32.8%-30.7%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
4/29/2026-1.3%-2.5%-1.9%
2/4/20268.9%22.4%7.9%
10/29/20254.9%4.0%11.2%
7/30/2025-36.6%-32.8%-30.7%
4/30/20252.0%-0.6%4.4%
2/5/20250.9%-5.1%-19.7%
10/23/20244.2%1.5%9.9%
7/24/2024-7.7%-5.3%-6.6%
4/24/2024-1.0%-9.3%-19.6%
1/31/20242.3%6.5%12.2%
10/25/2023-24.9%-27.8%-13.5%
7/26/202313.4%8.1%3.2%
4/26/2023-10.4%-14.5%-21.0%
2/1/202327.4%18.5%18.4%
10/26/2022-18.1%-19.2%-12.2%
7/27/20227.5%9.0%4.0%
4/27/2022-15.5%-13.7%-23.7%
2/2/2022-0.5%8.0%-8.1%
10/27/20214.5%11.5%4.9%
7/28/20218.9%13.9%12.0%
4/28/2021-1.5%-7.2%-2.2%
2/3/202112.6%10.9%-1.8%
10/21/202035.0%30.9%31.4%
7/22/2020-6.0%-5.6%-6.5%
SUMMARY STATS   
# Positive131211
# Negative111213
Median Positive7.5%9.9%9.9%
Median Negative-7.7%-8.3%-12.2%
Max Positive35.0%30.9%31.4%
Max Negative-36.6%-32.8%-30.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/06/202610-Q
12/31/202502/27/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202402/28/202510-K
09/30/202411/05/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/28/202410-K
09/30/202311/03/202310-Q
06/30/202308/04/202310-Q
03/31/202305/05/202310-Q
12/31/202202/27/202310-K
09/30/202211/04/202210-Q
06/30/202208/04/202210-Q
Collapse to Preview
Report DateFiling DateFiling
03/31/202605/06/202610-Q
12/31/202502/27/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/08/202510-Q
12/31/202402/28/202510-K
09/30/202411/05/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/28/202410-K
09/30/202311/03/202310-Q
06/30/202308/04/202310-Q
03/31/202305/05/202310-Q
12/31/202202/27/202310-K
09/30/202211/04/202210-Q
06/30/202208/04/202210-Q
03/31/202205/05/202210-Q
12/31/202102/25/202210-K
09/30/202111/02/202110-Q
06/30/202108/04/202110-Q
03/31/202105/05/202110-Q
12/31/202002/26/202110-K
09/30/202010/30/202010-Q
06/30/202007/31/202010-Q
03/31/202005/05/202010-Q
12/31/201902/28/202010-K
09/30/201910/31/201910-Q
06/30/201908/01/201910-Q

Recent Forward Guidance

Updated 5/31/2026

Latest: Q1 2026 Earnings Reported 4/29/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q2 2026 Revenue1.04 Bil1.05 Bil1.06 Bil2.9% RaisedGuidance: 1.02 Bil for Q1 2026
Q2 2026 Revenue Growth3.0%4.0%5.0%00Same NewGuidance: 4.0% for Q1 2026
Q2 2026 GAAP Operating Margin 16.4% 30.2%3.8%Higher NewGuidance: 12.6% for Q1 2026
Q2 2026 Non-GAAP Operating Margin 21.5% 10.3%2.0%Higher NewGuidance: 19.5% for Q1 2026
2026 Revenue Growth3.0%3.5%4.0%00AffirmedGuidance: 3.5% for 2026
2026 GAAP Operating Margin 18.0% 00AffirmedGuidance: 18.0% for 2026
2026 Non-GAAP Operating Margin 23.7% 00AffirmedGuidance: 23.7% for 2026
2026 Capital Expenditures125.00 Mil137.50 Mil150.00 Mil0 AffirmedGuidance: 137.50 Mil for 2026
2026 Share Repurchases 200.00 Mil   Higher NewGuidance: 0 for 2026

Prior: Q4 2025 Earnings Reported 2/4/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue1.01 Bil1.02 Bil1.03 Bil-1.4% LoweredGuidance: 1.03 Bil for Q4 2025
Q1 2026 Revenue Growth3.0%4.0%5.0%   
Q1 2026 GAAP Operating Margin12.4%12.6%12.8%-19.0%-3.0%LoweredGuidance: 15.55% for Q4 2025
Q1 2026 Non-GAAP Operating Margin 19.5% -25.0%-6.5%LoweredGuidance: 26.0% for Q4 2025
2026 Revenue Growth3.0%3.5%4.0% 3.5%Higher NewGuidance: 0.0% for 2025
2026 GAAP Operating Margin 18.0% 31.4%4.3%Higher NewGuidance: 13.7% for 2025
2026 Non-GAAP Operating Margin 23.7% 5.3%1.2%Higher NewGuidance: 22.5% for 2025
2026 Capital Expenditures125.00 Mil137.50 Mil150.00 Mil37.5% Higher NewGuidance: 100.00 Mil for 2025

Q3 2025 Earnings Reported 10/29/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q4 2025 Revenue1.02 Bil1.03 Bil1.04 Bil6.2% RaisedGuidance: 975.00 Mil for Q3 2025
Q4 2025 GAAP Gross Margin65.5%65.75%66.0%1.9%1.2%RaisedGuidance: 64.5% for Q3 2025
Q4 2025 GAAP Operating Margin15.3%15.55%15.8%41.4%4.6%RaisedGuidance: 11.0% for Q3 2025
2025 GAAP Operating Margin13.6%13.7%13.8%1.5%0.2%RaisedGuidance: 13.5% for 2025
2025 Capital Expenditures 100.00 Mil -11.1% LoweredGuidance: 112.50 Mil for 2025

Insider Activity

Updated 5/22/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morici, JohnEVP, CHIEF FINANCIAL OFFICERDirectSell2202026189.317,9691,508,6461,559,382Form
2Hogan, Joseph MPRESIDENT AND CEODirectBuy8012025131.497,576996,13124,317,512Form
3Coletti, Julie AnnEVP, CHIEF LEGAL & REGULATORYDirectBuy8012025109.66424,606779,672Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Morici, JohnEVP, CHIEF FINANCIAL OFFICERDirectSell2202026189.317,9691,508,6461,559,382Form
2Hogan, Joseph MPRESIDENT AND CEODirectBuy8012025131.497,576996,13124,317,512Form
3Coletti, Julie AnnEVP, CHIEF LEGAL & REGULATORYDirectBuy8012025109.66424,606779,672Form
Core Cache Last Updated: 7/7/2026